Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
197
Stocks News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
Does this bank have what it takes to compete with the big 4?
Organic growth and a recent acquisition were the focus of their investor day.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.80 | 20.30 | -0.23% |
| CAC 40 | 8,085.23 | 23.20 | -0.29% |
| DAX 40 | 24,155.96 | 109.95 | 0.46% |
| Dow JONES (US) | 47,739.32 | 215.67 | -0.45% |
| FTSE 100 | 9,648.28 | 3.19 | 0.03% |
| HKSE | 25,434.23 | 331.13 | -1.29% |
| NASDAQ | 23,545.90 | 32.22 | -0.14% |
| Nikkei 225 | 50,655.10 | 73.16 | 0.14% |
| NZX 50 Index | 13,454.78 | 31.54 | -0.23% |
| S&P 500 | 6,846.51 | 23.89 | -0.35% |
| S&P/ASX 200 | 8,585.90 | 20.50 | -0.24% |
| SSE Composite Index | 3,909.52 | 14.56 | -0.37% |